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Objective:  To  determine  the  prognostic  value  of  tumor  necrosis  at  computed  tomography  (CT) in  newly
diagnosed  diffuse  large  B-cell  lymphoma  (DLBCL).
Materials and methods:  This  retrospective  study  included  51  patients  with  newly  diagnosed  DLBCL  who
had  undergone  both  unenhanced  and  intravenous  contrast-enhanced  CT  before  R-CHOP  (rituximab,
cyclophosphamide,  hydroxydaunorubicin,  oncovin  and  prednisolone)  chemo-immunotherapy.  Presence
of tumor  necrosis  was  visually  and  quantitatively  assessed  at CT.  Associations  between  tumor  necrosis
status  at  CT  and  the  National  Comprehensive  Cancer  Network  (NCCN)  International  Prognostic  Index  (IPI)
factors were  assessed.  Cox  regression  analysis  was  used  to determine  the  prognostic  impact  of  NCCN-IPI
scores and  tumor  necrosis  status  at CT.
Results:  There  were  no correlations  between  tumor  necrosis  status  at CT  and the  NCCN-IPI  factors  cate-
gorized  age  (  = −0.042,  P  = 0.765),  categorized  lactate  dehydrogenase  (LDH)  ratio  (  =  0.201,  P =  0.156),
extranodal  disease  in major  organs  (ϕ =  −0.245,  P = 0.083),  Ann  Arbor  stage  III/IV  disease  (ϕ =  −0.208,
P  = 0.141),  and  Eastern  Cooperative  Oncology  Group  (ECOG)  performance  status  (ϕ  = 0.015,  P =  0.914).  In
the multivariate  Cox proportional  hazards  model,  only tumor  necrosis  status  at  CT  was  an  independent
predictive  factor  of  progression-free  survival  (P = 0.003)  and  overall  survival  (P = 0.004).
Conclusion: The  ﬁndings  of this  study  indicate  the  prognostic  potential  of  tumor  necrosis  at CT in newly
diagnosed  DLBCL.
© 2014 Elsevier  Ireland  Ltd.  All  rights  reserved.. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most com-
on  subtype of non-Hodgkin lymphoma, accounting for 30–35%
f cases [1]. Despite overall improvements in outcomes of
LBCL, particularly with the advent of R-CHOP (rituximab,
yclophosphamide, hydroxydaunorubicin, oncovin and pred-
isolone) chemo-immunotherapy, approximately one-third of
atients still develop relapsed/refractory disease that remains a
ajor cause of morbidity and mortality [2]. Early identiﬁcation
f patients who will experience relapsed/refractory disease is of
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niversity Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The
etherlands. Tel.: +31 88 7556687; fax: +31 30 2581098.
E-mail address: h.j.a.adams@gmail.com (H.J.A. Adams).
ttp://dx.doi.org/10.1016/j.ejrad.2014.12.009
720-048X/© 2014 Elsevier Ireland Ltd. All rights reserved.importance, because this will allow for the noninitiation or early
discontinuation of ineffective standard front-line R-CHOP therapy,
and provide a timely opportunity to switch to potentially more
effective therapies. The International Prognostic Index (IPI) and its
successors R-IPI and NCCN-IPI allow for risk stratiﬁcation [3–5],
but are insufﬁciently accurate to identify those patients in whom
R-CHOP chemo-immunotherapy is likely going to fail. There is an
active search for new prognostic biomarkers in DLBCL [1,2].
Imaging plays an important role in the evaluation of diffuse large
B-cell lymphoma, and is done by means of computed tomography
(CT), either as CT alone or in combination with 18F-ﬂuoro-2-deoxy-
d-glucose positron emission tomography (FDG-PET/CT) [6]. In the
pretreatment setting, the main role of imaging is to detect and
deﬁne the extent of disease for Ann Arbor staging and subse-
quent therapy response assessment. However, imaging ﬁndings
may  potentially also be useful to identify patients who are suffering
from treatment-resistant DLBCL subtypes. CT scans of patients with
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LBCL sometimes show tumor necrosis. Tumor necrosis shown at
T may  indicate that the underlying DLBCL has an aggressive tumor
rowth. However, it is still unknown whether this phenomenon has
ny prognostic implications in DLBCL.
The purpose of this study was to determine the prognostic value
f tumor necrosis at CT in newly diagnosed DLBCL patients who  are
reated with R-CHOP chemo-immunotherapy.
. Materials and methods
.1. Study design and patients
Local institutional review board approval was obtained for this
etrospective study, and the requirement for written informed
atient consent was waived. Any patient presenting with newly
iagnosed DLBCL routinely undergoes pretreatment FDG-PET/CT
t our institution. The hospital’s database was searched for all
atients with newly diagnosed DLBCL, who presented between
eptember 2007 and December 2013. Inclusion criteria for this
tudy were: newly diagnosed and histologically proven DLBCL,
vailability of both non-intravenous contrast-enhanced low-dose
T and intravenous contrast-enhanced full-dose CT from skull base
o upper thigh as part of the same FDG-PET/CT examination that
as performed on the same day, availability of blind bone mar-
ow biopsy (BMB) of the posterior iliac crest and serum lactate
ehydrogenase (LDH) measurement, and treatment with R-CHOP
hemo-immunotherapy. Exclusion criteria for this study were:
rimary mediastinal DLBCL (which is recognized as a separate dis-
ase entity), previously treated/relapsed lymphoma, transformed
ymphoma, coexistence of a second lymphoma subtype in the diag-
ostic biopsy, another cancer within the past ﬁve years, start of
herapy before FDG-PET/CT.
.2. Image acquisition
Non-intravenous contrast-enhanced low-dose CT and intra-
enous contrast-enhanced full-dose CT were acquired as part of
n FDG-PET/CT examination, using a 40-detector row PET/CT sys-
em (Biograph 40 TruePoint PET/CT, Siemens Healthcare). Patients
ngested a radio-opaque oral CT contrast agent (Telebrix Gastro,
uerbet) and fasted for 6 h before receiving 3 MBq/kg body weight
f FDG intravenously. Sixty minutes after FDG injection, low-dose
T images from skull base to upper thigh were acquired using
he following settings: 120 kV, 26–30 mAs  (automatic dose mod-
lation), 0.8-s tube rotation time, pitch of 1.2, and 1.5-mm slice
idth (reconstructed to contiguous 5-mm axial slices to match the
lice thickness of the PET images). PET scanning was performed
rom mid  femur to base of skull in ﬁve or six bed positions, with
 min  per bed position. Non-intravenous contrast-enhanced low-
ose CT data were used for PET attenuation correction. PET images
ere reconstructed with an ordered-subsets expectation maxi-
ization algorithm for 14 subsets and four iterations. The image
econstruction matrix was 128 × 128. Finally, a non-ionic iodinated
ontrast agent (Xenetix 300, Guerbet; 3 mL/s with bolus tracking)
as administered intravenously, and full-dose CT from skull base
o midthigh was performed in the portal venous phase using the
ollowing settings: 120 kV, 60–160 mAs  (automatic dose modula-
ion), 0.8-second tube rotation time, pitch of 1.2, and 1.5-mm slice
idth.
.3. Image interpretationAn experienced reader (T.C.K.) evaluated the combination of
on-intravenous contrast-enhanced low-dose CT and intravenous
ontrast-enhanced full-dose CT for the presence of tumor necro-
is. The reader was blinded to clinical and laboratory ﬁndings,f Radiology 84 (2015) 372–377 373
ﬁndings of other imaging modalities, BMB ﬁndings, and patient
outcome. Lymph nodes with a short-axis diameter exceeding
10 mm  in the axial plane were considered positive for lym-
phoma. Any area of abnormal attenuation or mass in extranodal
organs was also considered positive for lymphoma. Splenomegaly
(i.e. splenic index exceeding 725 cm3 [7]) was considered pos-
itive for lymphoma, but hepatomegaly without any focal liver
lesions was  not. Tumor necrosis was  considered present if low-
attenuation areas were visually identiﬁed in nodal or extranodal
lymphomatous sites with corresponding Hounsﬁeld units (HU)
measuring between 10 and 30 Hounsﬁeld units [8], and with-
out any (relevant) HU increase (up to a maximum of 5 HU)
between non-intravenous contrast-enhanced low-dose CT and
intravenous contrast-enhanced full-dose CT images, as determined
by region of interest analysis (ROI) (Figs. 1 and 2). Size-adjustable
oval-shaped ROIs were used for this purpose. Sites of necro-
sis and corresponding HU values measured in the center of the
necrotic area at intravenous contrast-enhanced full-dose CT were
recorded.
2.4. National Comprehensive Cancer Network (NCCN)
International Prognostic Index (IPI)
Age, serum LDH levels, presence of extranodal disease
in major organs (either bone marrow, central nervous sys-
tem, liver/gastrointestinal tract or lung), presence of Ann
Arbor stage III/IV disease, and Eastern Cooperative Oncology
Group (ECOG) performance status score of each patient were
recorded, at time of diagnosis, in order to calculate an NCCN-
IPI score, as described previously [5]. The four NCCN-IPI risk
groups (low [scores 0–1], low-intermediate [scores 2–3], high-
intermediate [scores 4–5] and high [scores 6–8]) were then
dichotomized into low risk (including low and low-intermediate
risk) and high risk (including high-intermediate and high risk)
groups.
2.5. Patient follow-up
Clinical follow-up and follow-up FDG-PET/CT were used in all
patients to determine if and when relapsed or progressive disease
had occurred during follow-up, according to the Revised Response
Criteria for Malignant Lymphoma [9]. Progression-free survival
(PFS) was  calculated from the date of diagnosis to documented
disease relapse/progression or, for patients dying as a result of
causes unrelated to DLBCL or the lymphoma treatment, the date
of death. For surviving patients who  did not experience disease
relapse/progression, follow-up was censored at the date the patient
was last known to be alive. Overall survival (OS) was calculated
from the date of diagnosis until death as a result of any cause
or, in surviving patients, censored at the date last known to be
alive.
2.6. Statistical analysis
Associations between tumor necrosis status at CT (i.e. tumor
necrosis absent or present) and the NCCN-IPI factors catego-
rized age (>40–60, >60–75, and >75 years), categorized LDH
ratio (>1–3 or ≥3 upper limit of normal), presence of extra-
nodal disease in major organs (either bone marrow, central
nervous system, liver/gastrointestinal tract or lung), presence of
Ann Arbor stage III/IV disease, and ECOG performance status (≥2)
were assessed using Spearman () (for ordinal NCCN-IPI factors)
or Phi (ϕ) (for binary NCCN-IPI factors) correlation coefﬁcient
analyses.
PFS and OS were assessed using the Kaplan–Meier method with
log-rank test [10], according to tumor necrosis status at CT (tumor
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Fig. 1. Example of tumor necrosis at CT in a 64-year-old man  with newly diagnosed DLBCL. Axial non-intravenous contrast-enhanced low-dose CT (a and c) and intravenous
contrast-enhanced full-dose CT (b and d) at the level of the lower neck, before (a and b) and after (c and d) ROI placement for HU measurement. Contrast-enhanced full-dose
CT  shows a left-sided pathologically enlarged cervical lymph node with central hypoattenuation (b, arrow), suggestive of necrosis in a lymphomatous lymph node. HU  value
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resence of necrosis.
ecrosis absent vs. tumor necrosis present) and dichotomized
CCN-IPI risk groups (low risk vs. high risk). Finally, univariate and
ultivariate Cox regression analyses were performed for tumor
ecrosis status at CT and dichotomized NCCN-IPI risk groups. All
ests were two-sided and P-values less than 0.05 were considered
o indicate a signiﬁcant difference.
Statistical analyses were executed using Statistical Package for
he Social Sciences version 17.0 (Chicago, Illinois, USA) and MedCalc
tatistical software version 12.6.0 (Ostend, Belgium).
ig. 2. Example of tumor necrosis at CT in a 49-year-old woman  with newly diagnosed DLB
ontrast-enhanced full-dose CT (b and d) at the level of the upper abdomen, before (a a
ull-dose CT shows a large hypoattenuating area in the spleen (b, arrow), suggestive of nec
as  24.8 before and 24.6 after intravenous contrast administration, indicating non-enhanavenous contrast administration, indicating non-enhancement and conﬁrming the
3. Results
3.1. Patients
A total of 121 patients presented with newly diagnosed and his-
tologically proven DLBCL, between September 2007 and December
2013, and were potentially eligible for inclusion. Of these 121
patients, 2 patients were excluded because of primary medi-
astinal DLBCL, 4 patients were excluded because of previously
CL. Axial non-intravenous contrast-enhanced low-dose CT (a and c) and intravenous
nd b) and after (c and d) ROI placement for HU measurement. Contrast-enhanced
rosis in a lymphomatous spleen. HU value of the hypoattenuating area in the spleen
cement and conﬁrming the presence of necrosis.
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Table  1
Characteristics of included patients.
Tumor necrosis at CT No tumor necrosis at CT
Patients (no.) 7 44
Age
Mean ± SD (years) 66.6 ± 10.6 65.8 ± 11.3
Median (years) 69.0 66.5
Range (years) 49–81 28–84
Male/female 5/2 27/17
NCCN-IPI factors
Age
≤40 years 0 1
>40  to ≤60 years 2 11
>60  to ≤75 years 4 22
>75  years 1 10
ECOG PS > 1 1 7
LDH  > ULN
≤1 0 15
>1  to ≤3 6 23
>3  1 6
Stage III/IV 5 40
Major extranodal involvementa 2 28
NCCN-IPI score
Low risk (0–1) 0 1
Low-intermediate risk (2–3) 1 9
High-intermediate risk (4–5) 6 22
High  risk (≥6) 0 12
Follow-up time of surviving patients
Mean ± SD (days) 423 ± 372 1045 ± 624
Median (days) 423 964
Range (days) 159–686 134–2386
Disease relapse or progression, or death (no.) 5 11
Death (no.) 5 9
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group Performance Score; LDH: lactate dehydrogenase; NCCN-IPI: National Comprehensive Cancer Network Interna-
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dional Prognostic Index; SD: standard deviation; ULN: upper limit of normal (accord
a Deﬁned as either bone marrow, central nervous system, liver/gastrointestinal
ervous system involvement, as recommended by Zhou et al. [5].
reated/relapsed lymphoma, 14 patients were excluded because
f a transformed lymphoma, 6 patients were excluded because
f coexistence of a second lymphoma subtype in the diagnostic
iopsy, 2 patients were excluded because of another cancer within
he past ﬁve years, 25 patients were excluded because of non-
vailability of intravenous contrast-enhanced full-dose CT from
kull base to upper thigh performed with use of the same PET/CT
ystem as non-intravenous contrast-enhanced low-dose CT on the
ame day, 12 patients were excluded because of absence of BMB,
nd 5 patients were excluded because of no or other treatment than
-CHOP chemo-immunotherapy. Thus, 51 patients (32 men  and 19
omen, mean age: 65.9 years, age range: 28–84 years) were ﬁnally
ncluded. Detailed patient characteristics are shown in Table 1.
.2. Tumor necrosis at CT
Tumor necrosis at CT was identiﬁed in 7 of 51 (13.7%) patients,
nd was located in the left cervical lymph nodes (n = 1), right
xillary lymph nodes (n = 1), mesenteric lymph nodes (n = 1), para-
ortal lymph nodes (n = 1), spleen (n = 2), and pelvic tumor mass
n = 1). Measured HU values of tumor necrosis ranged between 13.9
nd 24.6 (mean ± standard deviation: 21.4 ± 3.5)..3. Follow-up
The median follow-up time of surviving patients was  1011 days
range: 134–2386 days). In total, 16 patients (31.4%) experienced
isease relapse/progression or death, and 14 patients (27.5%) died. the local reference values of each participating institution).
or lung involvement, with histological conﬁrmation of bone marrow and central
3.4. Prognostic performance of tumor necrosis status at CT
There were no correlations between tumor necrosis status at
CT and the NCCN-IPI factors categorized age ( = −0.042, P = 0.765)
categorized LDH ratio ( = 0.201, P = 0.156), presence of extranodal
disease in major organs ( = −0.245, P = 0.083), presence of Ann
Arbor stage III/IV disease (ϕ = −0.208, P = 0.141), and ECOG perfor-
mance status (ϕ = 0.015, P = 0.914).
Five of seven (71.4%) patients with tumor necrosis died dur-
ing follow-up, 3 because of treatment-resistant DLBCL, 1 because
of relapsed DLBCL and 1 because of treatment-related complica-
tions. Patients with tumor necrosis at CT had signiﬁcantly worse
PFS and OS than patients without tumor necrosis at CT (log-rank
test, P = 0.001 and P = 0.001, respectively) (Fig. 3). On  the other hand,
there were no signiﬁcant differences in PFS and OS between low risk
and high risk NCCN-IPI groups (log-rank test, P = 0.100 and P = 0.171,
respectively) (Fig. 4). Univariate Cox regression analysis showed
that only tumor necrosis status at CT was a signiﬁcant predictor
of both PFS and OS (P = 0.003 and P = 0.004, respectively), whereas
dichotomized NCCN-IPI risk group was not (P = 0.135 and P = 0.203,
respectively). In the multivariate Cox proportional hazards model,
only tumor necrosis status (P = 0.003 and P = 0.004, respectively)
was an independent predictive factor of PFS and OS (Table 2).
4. DiscussionThe results of this study indicate that tumor necrosis at CT
may  be used as an imaging biomarker for assessing prognosis in
newly diagnosed DLBCL patients who  are treated with R-CHOP
chemo-immunotherapy. Patients with tumor necrosis at CT had
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Fig. 3. Kaplan–Meier curves for PFS (a) and OS (b) of patients with tumor necrosis at CT vs. patients without tumor necrosis at CT. Patients with tumor necrosis at CT had
signiﬁcantly worse PFS and OS than patients without tumor necrosis at CT (log-rank test, P = 0.001 and P = 0.001, respectively).
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Cig. 4. Kaplan–Meier curves for PFS (a) and OS (b) of patients with low risk NCCN-
S  between low risk and high risk NCCN-IPI groups (log-rank test, P = 0.100 and P =
 signiﬁcantly worse outcome in terms of both PFS and OS than
hose without tumor necrosis at CT. Tumor necrosis status at CT
as found not to be associated with any of the established NCCN-IPI
actors, including age, LDH ratio, presence of extranodal disease in
ajor organs, presence of Ann Arbor stage III/IV disease, and ECOG
erformance status, indicating that it can be used as an indepen-
ent prognostic factor. Interestingly, tumor necrosis status at CT
ven outperformed the dichotomized NCCN-IPI risk stratiﬁcation
n this study. Although the relatively low sample size of this study
ay  explain the lack of prognostic value of the NCCN-IPI, it signiﬁes
he prognostic potential of tumor necrosis status at CT. In addition,
t should be realized that current risk stratiﬁcation indices, includ-
ng the NCCN-IPI [3–5], are insufﬁciently accurate to identify the
ne-third of DLBCL patients who will develop relapsed/refractory
isease [2]. Given the fact that CT is routinely performed in most
able 2
ox regression analysis of progression free surival (PFS) and overall survival (OS).
Characteristic Univariate analysis PFS 
Hazard ratio 95% CI 
Tumor necrosis at CT vs. no tumor necrosis at CT 5.079 1.725–14
NCCN-IPI high risk vs. NCCN-IPI low risk 4.682 0.625–35
Characteristic Univariate analysis OS 
Hazard ratio 95% CI 
Tumor necrosis at CT vs. no tumor necrosis at CT 5.179 1.726–1
NCCN-IPI high risk vs. NCCN-IPI low risk 3.751 0.4953–2res vs. high risk NCCN-IPI scores. There were no signiﬁcant differences in PFS and
, respectively).
patients with newly diagnosed DLBCL, this new imaging biomarker
is readily available and does not result in additional costs.
Two previous studies have investigated the prognostic implica-
tions of tumor necrosis at CT in lymphoma [8,11]. In 1990, Hopper
et al. [8] investigated chest CT scans of 76 patients with newly diag-
nosed Hodgkin lymphoma with mediastinal involvement. CT scans
showed necrotic lymph nodes in 16 (21%) patients. The difference
between these patients and those without necrotic nodes was  not
statistically signiﬁcant with respect to sex, age, stage, distribution
of disease, presence of extranodal disease, cell type, mass diameter,
or the presence of bulky disease. In addition, Kaplan–Meier analyses
showed no differences between patients with necrotic mediastinal
lymph nodes and those without, both with regard to their length
of remission (P = 0.35) and their overall survival (P = 0.25). Hopper
et al. [8] concluded that the presence of mediastinal necrotic lymph
Multivariate analysis PFS
P-value Hazard ratio 95% CI P-value
.957 0.003 5.079 1.725–14.957 0.003
.095 0.135 – – –
Multivariate analysis OS
Hazard ratio 95% CI Hazard ratio 95% CI
5.543 0.004 5.179 1.726–15.543 0.004
8.410 0.203 – – –
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odes appears to have little prognostic signiﬁcance in patients with
ewly diagnosed Hodgkin lymphoma. There are important differ-
nces between Hopper et al.’s study [8] and the present study.
irst, their study dealt with Hodgkin lymphoma [8], which has a
ore favorable prognosis than DLBCL [12]. Moreover, Hopper et al.
8] only evaluated mediastinal lymph nodes, whereas the present
tudy evaluated both nodal and extranodal sites, from skull base
o upper thigh. Furthermore, unlike Hopper et al.’s study [8], the
resent study used both non-intravenous contrast-enhanced low-
ose CT and intravenous contrast-enhanced full-dose CT for the
ssessment of tumor necrosis, with non-enhancement as criterion
or tumor necrosis. As has already been acknowledged by Hop-
er et al. [8], differentiation between necrosis and other causes of
ow-attenuation tumor areas (e.g. oedematous but viable tumor tis-
ue) at intravenous contrast-enhanced CT only may  be difﬁcult. It
hould be noted that if the prognostic potential of tumor necro-
is at CT is conﬁrmed by future studies, both non-intravenous and
ntravenous contrast-enhanced CT may  be considered necessary for
retreatment evaluation of DLBCL. This contradicts with the recom-
endations of recent studies that intravenous contrast-enhanced
ull-dose CT can be omitted from an FDG-PET/CT staging examina-
ion in lymphoma [13,14]. The recent development of integrated
ET/magnetic resonance imaging might be an alternative strategy
or determining whether necrotic lymph nodes are present or not,
bviating the need for intravenous contrast-enhanced CT. How-
ver, sufﬁcient data supporting this hypothesis are still lacking. In
nother study in 2001, Saito et al. [11] evaluated CT and MRI  scans of
0 patients with different non-Hodgkin lymphoma subtypes for the
resence or absence of spontaneous extensive necrosis in the lym-
homatous nodes, before initiation of radiation or chemotherapy.
xtensive necrotic lymph nodes were found in 15 (25%) patients.
atients with necrosis had signiﬁcantly higher stages (Ann Arbor
tage ≥II), greater IPI (≥2), and higher serum LDH levels than those
ithout necrosis (P = 0.001, P = 0.005, and P = 0.005, respectively).
aplan–Meier analyses for disease-free survival showed a signiﬁ-
ant difference for serum LDH levels (P = 0.015) and IPI (P = 0.021),
ut not for extensive necrosis (P = 0.600). Saito et al. [11] concluded
hat spontaneous extensive necrosis in lymphomatous nodes is not
 rare event. In addition, they concluded that although this ﬁnding
ad no signiﬁcant inﬂuence on disease-free survival in their small
eries of patients, spontaneous extensive necrosis may  have a pro-
nostic signiﬁcance in patients with non-Hodgkin lymphomas [11].
he major limitation of Saito et al.’s study is the fact that different
on-Hodgkin lymphoma subtypes (4 low-grade, 53 intermediate-
rade, and 3 high-grade) were included and analyzed all together
11], although treatment and outcome of different non-Hodgkin
ymphoma subtypes varies considerably [15]. In addition, Saito
t al.’s study suffered from selection bias, because only patients
eferred for radiation therapy with or without chemotherapy were
ncluded [11]. Furthermore, Saito et al. [11] only evaluated for the
resence of necrosis in lymph nodes and not in extranodal sites.
This study had several limitations. First, several patients who
ere potentially eligible for enrolment into this study had to
e excluded, mainly because no intravenous contrast-enhanced
ull-dose CT was performed at the time of the FDG-PET/CT exam-
nation. This is due to the fact that these patients had already
ndergone intravenous contrast-enhanced full-dose CT before the
DG-PET/CT examination, because the diagnosis of DLBCL was not
nown yet. Although these patients had to be excluded to avoid
ny potential time-related difference in disease status between
on-intravenous contrast-enhanced low-dose CT and intravenous
ontrast-enhanced full-dose CT, this is unlikely to have caused any
[f Radiology 84 (2015) 372–377 377
selection bias. Second, because of the retrospective nature of this
study, histopathological analysis of necrotic tumor sites at CT was
not available. In the study by Saito et al. [11], histopathological anal-
ysis in 10 of 15 patients with necrotic lymph nodes showed that
all the lymph nodes were completely involved with lymphoma-
tous cells, including sinus and hila of the lymph nodes, and that
almost all of the lymphomatous cells developed necrosis. Although
the pathogenesis of tumor necrosis at CT in DLBCL remains unclear,
it can be speculated that it indicates aggressive tumor growth with
an apparent tendency for treatment resistance.
In conclusion, the ﬁndings of this study indicate the prognostic
potential of tumor necrosis at CT in newly diagnosed DLBCL. Future
prospective studies with larger sample sizes are required to validate
the prognostic potential of this new imaging biomarker.
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